Company / Working Capital
Marker Therapeutics, Inc. Working Capital History
FY2018-FY2021 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Working Capital
$33.1M
FY2021
5-year range
$33.1M / $59.2M
FY2018-FY2021
Trend
-23.9%
vs FY2020
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from $59M to $33M over the past 3 years.
Based on SEC 10-K filings.
$33M in FY2021.
Declined from $59M to $33M over the past 3 years.
Working Capital over time
Growth rates
- 3-Year CAGR
- -17.6%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- 3-year CAGR of -17.6%, indicating a declining trend.
- In FY2021, working capital decreased 23.9% year-over-year.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -5.64 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Working CapitalValue | YoY GrowthYoY |
|---|---|---|
| FY2021 | $33.1M | -23.9% |
| FY2019 | $43.5M | -26.5% |
| FY2018 | $59.2M | - |
As of FY2021 · SEC 10-K · Updated Jun 28, 2026